Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook

Merck & Co. reported robust third-quarter results, with adjusted EPS of $2.58 and sales of $17.28 billion, both surpassing consensus estimates, driven by strong performance in oncology and new products like Winrevair, despite a 24% decline in GARDASIL sales due to lower China demand. The company subsequently raised its fiscal 2025 adjusted EPS guidance and narrowed its sales outlook, while also reaffirming its M&A strategy targeting deals primarily between $1 billion and $15 billion, with flexibility for larger acquisitions.

Analysis

Merck & Co. (MRK) reported robust third-quarter results, with adjusted EPS of $2.58 significantly surpassing consensus estimates of $2.35, and sales reaching $17.28 billion, exceeding projections of $16.96 billion. This 4% year-over-year sales increase was primarily driven by the pharmaceutical segment's 4% growth ($15.61 billion), fueled by strong performance in oncology, cardiovascular, and diabetes franchises. Keytruda sales rose 10% to $8.14 billion, and new product Winrevair saw a 141% sales jump to $360 million.

Despite overall strength, the vaccine segment, specifically GARDASIL, experienced a 24% decline in sales to $1.75 billion, attributed to lower demand in China. However, the company raised its fiscal 2025 adjusted EPS guidance to $8.93-$8.98, up from $8.87-$8.97, exceeding the Wall Street estimate of $8.91, while narrowing its sales outlook to $64.5 billion-$65 billion.

Management reiterated its M&A strategy, targeting deal sizes primarily between $1 billion and $15 billion, while expressing willingness to pursue larger acquisitions for pipeline expansion. The stock traded with slight volatility post-announcement, closing up 0.07% at $86.64, reflecting a generally positive market reception to the earnings beat and guidance update.

Key Decisions for Investors

• Monitor Keytruda's sustained growth and the contribution of new therapies like Winrevair to overall revenue, given their significant impact on recent results.
• Evaluate the implications of the GARDASIL sales decline in China and potential mitigation strategies on future vaccine segment performance.
• Consider Merck's reiterated M&A strategy, particularly its stated deal size preferences, as a potential driver for pipeline expansion and long-term value creation.